A Single Centre, Two Treatment, Two Period, Two Sequence, Randomized Crossover Steady-state Relative Bioavailability Study of Naproxen in Two Tablet Formulations Given Twice Daily (PN 400 Tablets Containing 500mg of Naproxen Plus 20mg of Esomeprazole Versus Naprosyn Containing Naproxen 500mg).

Trial Profile

A Single Centre, Two Treatment, Two Period, Two Sequence, Randomized Crossover Steady-state Relative Bioavailability Study of Naproxen in Two Tablet Formulations Given Twice Daily (PN 400 Tablets Containing 500mg of Naproxen Plus 20mg of Esomeprazole Versus Naprosyn Containing Naproxen 500mg).

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2010

At a glance

  • Drugs Esomeprazole/naproxen; Naproxen
  • Indications Ankylosing spondylitis; Musculoskeletal pain; Osteoarthritis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top